The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Open accessAbstract
Anaplastic lymphoma kinase (ALK) activation has been associated with many types of human cancer. Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK. Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-positive non-small cell lung cancers (NSCLC). However, drug resistance has been observed in the majority of patients treated with these inhibitors. New therapeutic strategies (e.g., compounds with novel mechanisms of action) are needed to overcome the drug resistance issue. The emerging PROTAC (Proteolysis Targeting Chimera) technology has been successfully applied to selective degradation of multiple protein targets, but not ALK. Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity. Here we report the design, synthesis and biological evaluation of novel PROTACs (degraders) of ALK. MS4077 (5) and MS4078 (6) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells. The ALK protein degradation induced by compounds 5 and 6 was cereblon and proteasome dependent. In addition, compounds 5 and 6 potently inhibited proliferation of SU-DHL-1 cells. Furthermore, compound 6 displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies. We also developed MS4748 (7) and MS4740 (8), very close analogs of 5 and 6 respectively, which are incapable to degrade the ALK fusion proteins, as negative controls. Compounds 5-8 are valuable chemical tools for investigating effects of ALK pharmacological degradation. Our study paved the way for developing the next generation of ALK PROTACs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, PROTACs were shown to be substrates for MDR1 (10, 13), suggesting that drug efflux represents a potential limitation for degrader therapies.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [13]
In the citing paper
“A number of PROTACs have been developed to target various POIs that are involved in the tumorigenesis and progression of hematologic malignancies, such as anaplastic lymphoma kinase (ALK) [5], Bcl-xL [4], BCR-ABL [6], Bruton’s tyrosine kinase (BTK) [7], BRD4 [8], CDK-6 [9], FMS-like tyrosine kinase-3 (FLT-3) [10], HDAC6 [11], and signal transducer and activator of transcription 3 (STAT3) [3].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [5]
In the citing paper
“Recently, the anaplastic lymphoma kinase (ALK) was degraded by two PROTACs based on a pomalidomide warhead targeting CRBN linked with either LDK378 (ceritinib) [79, 80] or TAE684 [79] targeting ALK.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
In the citing paper
“Both PROTACs were able to reduce downstream signalling and proliferation of ALK-driven cell lines by degrading ALK [79, 80].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Cited by
Sorted by citations
Items 101–200 of 249
Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation
Zhu, X., Liu, H., Chen, L., Wu, C., Liu, X., Cang, Y., Jiang, B., Yang, X., & Fan, G. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.10.007 · Cited by 38
Self-citationALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Poei, D., Ali, S., Ye, S., & Hsu, R. C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.25 · Cited by 36
Genetic fusions favor tumorigenesis through degron loss in oncogenes
Liu, J., Tokheim, C. J., Lee, J. D., Gan, W., North, B. J., Liu, X. S., Pandolfi, P. P., & Wei, W. (2021) · Nature Communications · doi:10.1038/s41467-021-26871-y · Cited by 34
Self-citationSimard, J. R., Lee, L., Vieux, E. F., Improgo, R., Tieu, T. N., Phillips, A. J., Fisher, S. L., Pollock, R. M., & Park, E. Y. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985049 · Cited by 33
Tan, L., & Gray, N. S. (2018) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800293 · Cited by 34
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
Shiah, J. V., Grandis, J. R., & Johnson, D. E. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0599 · Cited by 32
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 32
Wang, S., Luo, D., Pu, C., Ma, X., Zhang, H., Feng, Z., Deng, R., Yu, S., Liu, Y., Huang, Q., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115082 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32
Shan, Y., Si, R., Wang, J., Zhang, Q., Li, J., Ma, Y., & Zhang, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112654 · Cited by 29
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Fan, L., Tong, W., Wei, A., & Mu, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133680 · Cited by 30
Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation
Wang, S., Feng, Z., Qu, C., Yu, S., Zhang, H., Deng, R., Luo, D., Pu, C., Zhang, Y., & Li, R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02340 · Cited by 29
Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
Lv, M.-Y., Hou, D., Liu, S., Cheng, D., & Wang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c11903 · Cited by 30
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
The roles of E3 ligases in Hepatocellular carcinoma.
Yu, Z., Li, H., Zhu, J., Wang, H., & Jin, X. (2022) · PubMed · Cited by 27
Proteolysis targeting chimeras in non-small cell lung cancer
Hagopian, G. G., Grant, C., & Nagasaka, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102561 · Cited by 26
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
Vicente, A. T. S., Moura, S. P. S. P., & Salvador, J. A. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01598-9 · Cited by 23
Cell-specific drug targeting in the lung
Abed, S., Turner, R. A., Serniuck, N. J., Tat, V., Naiel, S., Hayat, A. I., Mekhael, O., Vierhout, M., Ask, K., & Rullo, A. F. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114577 · Cited by 21
ASDs of PROTACs: Spray-dried solid dispersions as enabling formulations
Hofmann, N., Harms, M., & Mäder, K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123725 · Cited by 21
Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein
Shibata, N., Ohoka, N., Hattori, T., & Naito, M. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00703 · Cited by 21
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Self-citationALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3
Hu, M., Bao, R., Lin, M., Han, X., Ai, Y., Gao, Y. L., Guan, K., Xiong, Y., & Yuan, H. (2022) · Oncogene · doi:10.1038/s41388-022-02453-0 · Cited by 20
Self-citationEmerging Target-Directed Approaches for the Treatment and Diagnosis of Microbial Infections
Almeida, M. C., da Costa, P. M., Sousa, E., & Resende, D. I. S. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01212 · Cited by 20
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 19
Light control of RTK activity: from technology development to translational research
Leopold, A. V., & Verkhusha, V. V. (2020) · Chemical Science · doi:10.1039/d0sc03570j · Cited by 18
Discovery of a miniaturized PROTAC with potent activity and high selectivity
Gong, L., Li, R., Gong, J., Ning, X., Sun, J., Ma, Q., Zhu, C., Yang, Y., Lin, K., Li, Y., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106556 · Cited by 19
CNS delivery of targeted protein degraders
Agarwal, P., Reid, D. L., & Amiji, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.057 · Cited by 19
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
Liu, S., Da, Y., Wang, F., Yan, R., Shu, Y., Lin, P., & Lin, J. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02526-3 · Cited by 17
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 17
Racioppo, B., Pechalrieu, D., Abegg, D., Dwyer, B. G., Ramseier, N. T., Hu, Y., & Adibekian, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17827 · Cited by 18
Updates in pathobiological aspects of anaplastic large cell lymphoma
Wu, R., & Lim, M. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1241532 · Cited by 16
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Lindner, S., Steinebach, C., Kehm, H., Mangold, M., Gütschow, M., & Krönke, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59472 · Cited by 18
Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation
Bai, M., Gallen, E., Memarzadeh, S., Howie, J., Gao, X., Kuo, C.-W. S., Brown, E. H., Swingler, S., Wilson, S. J., Shattock, M. J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299665 · Cited by 16
Cordani, N., Nova, D., Sala, L., Abbate, M. I., Colonese, F., Cortinovis, D. L., & Canova, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011214 · Cited by 18
Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Qi, J., & Zhang, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0557 · Cited by 15
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
Torres‐Ayuso, P., & Brognard, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000306 · Cited by 15
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14
LG-ESSs and HG-ESSs: underlying molecular alterations and potential therapeutic strategies
Li, C., & Wang, C. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000797 · Cited by 14
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 14
Precise Modulation of Protein Degradation by Smart PROTACs
Cheng, J., Dong, G., Wang, W., & Sheng, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400682 · Cited by 13
Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Mukhamejanova, Z., Tong, Y., Xiang, Q., Xu, F., & Pang, J. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312112412 · Cited by 13
Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers
Zhou, H., Hu, M., Jie, H., Li, Y., Tang, K., Pan, L., Liu, C., Liu, Z., Chen, W., Chen, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116827 · Cited by 12
Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy
Chen, L., Wan, X., Shan, X., Zha, W., & Fan, R. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00586-2 · Cited by 13
DNA-modularized construction of bivalent ligands precisely regulates receptor binding and activation
Zhao, N., Wu, W., Wang, Y., Song, K., Chen, G., Chen, Y., Wang, R., Xu, J., Cui, K., Chen, H., et al. (2023) · Chem · doi:10.1016/j.chempr.2022.12.002 · Cited by 12
PROTACting the kinome with covalent warheads
Chatterjee, D. R., Kapoor, S., Jain, M., Das, R., Chowdhury, M. G., & Shard, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103417 · Cited by 12
Marini, E., Marino, M., Gionfriddo, G., Maione, F., Pandini, M., Oddo, D., Giorgis, M., Rolando, B., Blua, F., Gastaldi, S., et al. (2022) · Molecules · doi:10.3390/molecules27238513 · Cited by 11
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Yang, Y., Zhao, C.-J., Jin, Z.-F., Zheng, J., & Ma, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120828 · Cited by 11
Gu-liang, Y., Zhong, H., Xia, X., Qi, Z., Wang, C., & Li, S. (2021) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.11.001 · Cited by 10
Yang, X., He, Y., Kim, R. D., Fleming, J. B., & Xie, H. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00782-2 · Cited by 10
Self-citationProgress on Small-Molecule Proteolysis-Targeting Chimeras
Huang, W., Wang, B., Zhang, Z., Zhang, C., Zeng, S., & Shen, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0161 · Cited by 10
Self-citationFDA-approved kinase inhibitors in PROTAC design, development and synthesis
Kossakowski, K., Cherniienko, A., Zaprutko, L., & Pawełczyk, A. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2542357 · Cited by 12
Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Murakami, Y., Ishida, S., Cho, N., Yuki, H., Ohta, M., Honma, T., Demizu, Y., & Terayama, K. (2026) · JACS Au · doi:10.1021/jacsau.6c00033 · Cited by 10
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 8
ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy
Liu, Q.-G., Wu, J., Wang, Z., Chen, B., Du, Y., Niu, J.-B., Song, J. H., & Zhang, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117646 · Cited by 8
Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy
Ohoka, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00113 · Cited by 8
Gao, H., Zhang, J., Zhao, L.-J., & Guo, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106807 · Cited by 7
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race
Ashton, J. C. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117214 · Cited by 7
Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death
Alraddadi, A. M., Smalley, J. P., Alzahrani, W., Saleh, A., Al-Mansour, F. S. H., He, B., Cao, T. H., Jayne, S., Dyer, M. J. S., Hodgkinson, J. T., et al. (2025) · eJHaem · doi:10.1002/jha2.70127 · Cited by 7
Li, X., Wang, Z., Chen, C., Yang, F., Liu, P., Wang, B., Wang, B., Chen, S., & Li, X. (2024) · iScience · doi:10.1016/j.isci.2024.109015 · Cited by 7
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins
Yokoo, H., Tsuji, G., Inoué, T., Naito, M., Demizu, Y., & Ohoka, N. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107204 · Cited by 7
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
Ying, S., Chi, H., Xiao-qiu, W., Zeng, P., Chen, J., Fu, T., Fu, W., Zhang, P., & Tan, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02417 · Cited by 8
Target engagement approaches for pharmacological evaluation in animal models
Kath, J. E., & Baranczak, A. (2019) · Chemical Communications · doi:10.1039/c9cc02824b · Cited by 8
Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
Wu, Y., Zhang, J., Zhu, X., & Zhang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215808 · Cited by 8
N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
Banerjee, S., Sharma, S., Thakur, A., Sachdeva, R., Sharma, R., Nepali, K., & Liou, J. (2023) · Current Drug Targets · doi:10.2174/0113894501273969231102095615 · Cited by 7
Li, M.-T., Liang, J.-Y., Sun, Y., Jin, J. J., Xiong, Y., Guan, K., & Yuan, H. (2019) · Biochemical Journal · doi:10.1042/bcj20190106 · Cited by 7
Self-citationFrom Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 6
PROTAC Enabling Formulation In Vivo: Implications of the Polymeric Carrier Eudragit E PO
Hofmann, N., Johann, F., Krollik, K., Marx, A., Duevel, H. M., Lecomte, M., Harms, M., & Mäder, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00303 · Cited by 6
PROTACs: Walking through hematological malignancies
Malhab, L. J. B., AlSafar, H. S., Ibrahim, S. M., & Rahmani, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1086946 · Cited by 6
PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
Cromm, P. M., Crews, C. M., & Weinmann, H. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00001 · Cited by 6
Khan, M. Z. I., Nazli, A., Pan, Y., & Chen, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220803112409 · Cited by 7
Wu, J., Wang, Z., Tan, S.-X., Li, T., Chen, B., Chen, Q., Li, H., Niu, J.-B., Fu, X.-J., Song, J., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109380 · Cited by 6
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
Conery, A. R., La, D. S., Alekseyenko, A. A., Marcoux, D., Bart, A. G., Harlow, M. L., Arsenault, P. R., Cantone, N. R., Casaubon, R. L., Constan, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10998-3 · Cited by 7
Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities
Jiang, Y., Tang, Z., Jiang, M., Wang, J., & Wang, Y. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70087 · Cited by 5
Discovery of an ALK degrader for lorlatinib-resistant compound mutations
Gao, F., Wu, Z., Lin, A., Wu, X., Zhang, B., Liu, L., Lu, Y., Geng, S., Huang, Z., Chen, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117835 · Cited by 5
Dual Kinase Targeting in Leukemia
Mologni, L., Marzaro, G., Redaelli, S., & Zambon, A. (2021) · Cancers · doi:10.3390/cancers13010119 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
Fan, Y., Liu, Y., Wang, L., Xu, H., Yu, L., Lang, Y., Li, H., Chen, F., & Feng, S. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114974 · Cited by 4
Novel therapeutic approaches targeting oxidative stress in breast and lung cancer
Kaushik, P., Kaushik, M., & Parvez, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90905-1.00010-9 · Cited by 4
Prakash, S., Tyagi, P., Singh, P., Rajkumar, R., & Singh, A. P. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096331827240911165227 · Cited by 8
[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].
Jiang, L., Zhang, J., Hu, J., Qi, H., & Xu, H. Y. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.19 · Cited by 4
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787-v · Cited by 4
Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors
Si, R., Hai, P., Zheng, Y., Liu, N., Wang, J., Zhang, Q., Li, Y., Pan, X., & Zhang, J. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129275 · Cited by 4
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch5 · Cited by 4
Discovery of KRAS-G12D degraders via exploration of various E3 ligases
Yim, H., Song, X., Zhong, Y., Hu, J., Xiong, Y., & Jin, J. J. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118635 · Cited by 3
Self-citationProspects and advances of PROTAC in the treatment of hematologic malignancies
Wang, X., Zhang, M., & Mei, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00759-3 · Cited by 3
PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
Feral, A., Laconde, G., Amblard, M., & Masurier, N. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000148 · Cited by 3
The past, present, and future of ALK-targeted drug discovery
Qu, H., Zhang, J., Zhao, X., Ge, X., Duan, L., & Yuan, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118053 · Cited by 2
Essa, K., Zacarı́as, N. V. O., Röth, S., Xin, B., de Winter, S., van der Horst, C., Bleijs, B. T. M., de Heiden, R. A., Voulgaraki, R., Neubert, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02920 · Cited by 3
Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115840 · Cited by 2
Zhu, C., Li, Y., Xu, H., Sun, L., Wei, Y., 马承娴, Chen, Q., & He, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02682-9 · Cited by 4
Christine, C., Pebriani, F., Faruq, M. A. A., Florencia, C., & Muchtaridi, M. (2022) · Indonesian Journal of Biological Pharmacy · doi:10.24198/ijbp.v2i1.38126 · Cited by 2
Therapeutic strategies to overcome ALK resistance in lung cancer
Recondo, G., & Friboulet, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00004-8 · Cited by 1
Cho, N., & Naito, M. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.09.001 · Cited by 1
Kim, B., Sheridan, R. P., Zhang, R., de Barros, E. P., Johnston, J. M., & Li, X. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01600 · Cited by 2
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1
Metadata
- Authors
- Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J.
- Affiliations
- Tisch Cancer Institute (US)
- ShanghaiTech University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Jing
- Xiong, Yue
- Jin, Jian
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 151
- Pages
- 304-314
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC5924614
- OpenAlex
- W2794623623
- Cited by
- 226
- References
- 57
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 24 · 2023: 26 · 2022: 31 · 2021: 31 · 2020: 38 · 2019: 26 · 2018: 9
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U. S. National Institutes of Health (R01GM067113)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, anaplastic lymphoma kinase, cereblon ligands, proteasomal degradation, ALK fusion proteins, drug resistance, non-small cell lung cancer, ALK-positive lymphoma, pharmacokinetics, kinase inhibitors
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Humans, Lung Neoplasms, Lymphoma, Male, Drug Design, Signal Transduction, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
